The Crohns Infection is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Here are some of the most recent developments in the area of MAP related Crohn’s Research. Enjoy!
The Crohn’s Infection is pleased to announce the newly created Dietzia Foundation! From their website, “Dietzia Foundation is a publicly supported nonprofit organization dedicated to supporting scientific medical research in the field of gastroenterology. Specifically, we support those trying to develop preventative or therapeutic treatments for gastrointestinal dysbiosis associated diseases like Crohn’s disease, ulcerative colitis and others.”
It doesn’t seem possible, but on June 21, 2016, The Crohn’s Infection site will officially be one year old. Join us as we highlight some of the key site features and enter our first site contest. Thanks for coming to the party!
On June 14, 2016, the journal Gut Pathogens released a new study entitled “RHB-104 Triple Antibiotics Combination in Culture is Bactericidal and Should be Effective for Treatment of Crohn’s Disease Associated with Mycobacterium paratuberculosis.” The researchers from the University of Central Florida (including Dr. Saleh Naser) found that the raw active ingredients used in RHB-104 worked together in combination to inhibit the growth of 16 Mycobacterium avium paratuberculosis (MAP) strains and 19 other mycobacterial species.
To all of the fathers out there: We hear you and acknowledge your love and strength in whatever health battle you are fighting. We support you. We care.
Christchurch Microbiologist May Have Cracked Crohn’s Disease
New today, two articles about John Aitken and his research into Crohn’s disease are making headlines in the New Zealand news.